Compare Campbell Soup Co. (CPB) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Cytokinetics Inc — how do they compare? Campbell Soup Co. trades at $22.79 (market cap $6.69B), while Cytokinetics Inc trades at $76.67 (market cap $10.78B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Campbell Soup Co. pays a 6.96% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CPB | CYTK | |
|---|---|---|
Market Cap | $6.69B | $10.78B |
Sector | Consumer Staples | Technology |
52-Week High | $34.03 | $87.26 |
52-Week Low | $20.00 | $34.31 |
Enterprise Value | $13.29B | $10.88B |
Dividend Yield | 6.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $23.05, up 2.17% with a bullish technical signal. The company shows stable revenue around $10B but faces margin pressure with net income margin at 6.12%. Recent earnings beat expectations in Q1 2026, while analyst sentiment remains cautious with only 3.45% buy ratings. The stock offers a 6.8% dividend yield, supported by positive cash flow from operations of $1.13B in 2025.
The outlook remains mixed with cost-saving initiatives and product innovation providing upside potential, but persistent margin challenges and high debt levels pose significant risks. Current valuation appears reasonable with P/E of 11.29, though weak analyst consensus suggests limited near-term catalyst for price appreciation beyond dividend income.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
